STAT+: Biotech launches with $82 million for Parkinson’s cell therapy

Kenai Therapeutics plans to move into a clinical trial within the year for its lead drug candidate for people with Parkinson’s.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks